Beyond PARP Inhibitors in Advanced Breast Cancer Patients with Germline BRCA1/2 Mutations: Focus on CDK4/6-Inhibitors and Data Review on Other Biological Therapies

SIMPLE SUMMARY: The treatment landscape for advanced breast cancer (BC) has been expanding due to the development of biological drugs with demonstrated efficacy across all breast cancer subtypes. The role of poly adenosine diphosphate–ribose polymerase (PARP) inhibitors in advanced BC is well establ...

Descripción completa

Detalles Bibliográficos
Autores principales: Nerone, Marta, Rossi, Lorenzo, Condorelli, Rosaria, Ratti, Vilma, Conforti, Fabio, Palazzo, Antonella, Graffeo, Rossella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340438/
https://www.ncbi.nlm.nih.gov/pubmed/37444415
http://dx.doi.org/10.3390/cancers15133305

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340438/
https://www.ncbi.nlm.nih.gov/pubmed/37444415
http://dx.doi.org/10.3390/cancers15133305

Ejemplares similares